Probability risk transmission matrix as a decision tool for assessing methods of transmission interruption of Wuchereria bancrofti infection
- PMID: 17579929
- PMCID: PMC2870840
- DOI: 10.1017/S0950268807008953
Probability risk transmission matrix as a decision tool for assessing methods of transmission interruption of Wuchereria bancrofti infection
Abstract
Lymphatic filariasis continues to cause severe morbidity and economic loss. The World Health Assembly (WHA) has passed a resolution to eliminate this disease by 2020. The major thrust of the elimination strategy is interrupting transmission by anti-parasitic treatment of entire communities. However, both vector density and community microfilaria load (CMFL) influence the intensity of transmission. Therefore, using a logistic regression approach a relationship has been established between the Risk of Infection Index (RII), vector density and CMFL. The present analysis indicates that there is no risk of transmission as long as the CMFL is maintained below 5 microfilaria (mf)/60 mm3 and the vector density per man-hour (MHD) is 25 and CMFL is <5 mf/60 mm3. In situations where CMFL is very high, parasitic control by mass administration may be cost effective in interrupting transmission. But at lower level of CMFL (<4 mf) and higher level of vector density it might be more cost effective to use vector control methods. A RII value <0.2 is considered to be the threshold for confirming interruption of transmission. Thus, the relationship has been depicted in the form of a probability matrix, which could be used for selecting an appropriate control strategy.
Figures
Similar articles
-
The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.Trop Med Int Health. 2003 Dec;8(12):1082-92. doi: 10.1046/j.1360-2276.2003.01138.x. Trop Med Int Health. 2003. PMID: 14641843 Clinical Trial.
-
Randomised community-based trial of annual single-dose diethylcarbamazine with or without ivermectin against Wuchereria bancrofti infection in human beings and mosquitoes.Lancet. 1998 Jan 17;351(9097):162-8. doi: 10.1016/S0140-6736(97)07081-5. Lancet. 1998. PMID: 9449870 Clinical Trial.
-
The effect of six rounds of single dose mass treatment with diethylcarbamazine or ivermectin on Wuchereria bancrofti infection and its implications for lymphatic filariasis elimination.Trop Med Int Health. 2002 Sep;7(9):767-74. doi: 10.1046/j.1365-3156.2002.00935.x. Trop Med Int Health. 2002. PMID: 12225508 Clinical Trial.
-
Current practices in the management of lymphatic filariasis.Expert Rev Anti Infect Ther. 2009 Jun;7(5):595-605. doi: 10.1586/eri.09.36. Expert Rev Anti Infect Ther. 2009. PMID: 19485799 Review.
-
Lymphatic filariasis in India: epidemiology and control measures.J Postgrad Med. 2010 Jul-Sep;56(3):232-8. doi: 10.4103/0022-3859.68650. J Postgrad Med. 2010. PMID: 20739779 Review.
Cited by
-
A community-based study of factors associated with continuing transmission of lymphatic filariasis in Leogane, Haiti.PLoS Negl Trop Dis. 2010 Mar 23;4(3):e640. doi: 10.1371/journal.pntd.0000640. PLoS Negl Trop Dis. 2010. PMID: 20351776 Free PMC article.
References
-
- Michael E, Bundy DAP, Grenfell BT. Re-assessing the global prevalence and distribution of lymphatic filariasis. Parasitology. 1996;112:409–428. - PubMed
-
- Michael E, Bundy DAP. Global mapping of lymphatic filariasis. Parasitology Today. 1997;13:472–476. - PubMed
-
- Ramaiah KD et al. The economic burden of lymphatic filariasis in India. Parasitology Today. 2000;16:251–253. - PubMed
-
- Ottesen EA, Campbell WC. Ivermectin in human medicine. Journal of Antimicrobial Chemotherapy. 1994;34:195–203. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources